Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 18/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048946 | 0.86 | GRM5 (0.42) | GRM5OGA | |
| SCHEMBL4536276 | 0.83 | GRM5 (0.40) | GRM5OGA | |
| SCHEMBL5090735 | 0.80 | GRM5 (0.43) | GRM5 | |
| SCHEMBL28811006 | 0.79 | GRM5 (0.47) | GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL8675743 | 0.79 | GRM5 (0.49) | GRM5 | |
| SCHEMBL2290995 | 0.77 | GRM5 (0.44) | GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2892482 | 0.76 | GRM5 (0.43) | GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL4053802 | 0.73 | GRM5 (0.43) | GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL4047546 | 0.70 | GRM5 (0.60) | GRM5 | |
| SCHEMBL4538188 | 0.70 | GRM5 (0.36) | GRM5ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989620-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-20100144771-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-7648992-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| EP-1778673-B1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | ASTRAZENECA AB (SE) | 2009-11-11 | — | — | EP | disclosed |
| CN-100543024-C | The hydantoin derivatives that is used for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2009-09-23 | — | — | CN | disclosed |
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| CN-1980914-A | Novel hydantoin derivatives for the treatment of obstructive airway diseases. | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | GRM5 2437/4885OGA 3840/4885ALDH1A1 81/4885 |
| US-20100144771-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | GRM5 2364/4885OGA 3852/4885ALDH1A1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.